Alcohol-free antimicrobial hand sanitizer

A polymer-based nanoemulsion system with CV-N, CBD, and palmitic acid in an alcohol-free hand sanitizer addresses the safety concerns of alcohol-based products by providing effective antimicrobial protection and skin moisturization, ensuring safety and efficacy against SARS-CoV-2 and other pathogens.

JP2024541437APending Publication Date: 2024-11-08COUNCIL FOR SCI IND RES
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024529813
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-17
Filing Date
2022-11-02
Publication Date
2024-11-08

Smart Images

  • Figure 2024541437000017
    Figure 2024541437000017
  • Figure 2024541437000018
    Figure 2024541437000018
  • Figure 2024541437000019
    Figure 2024541437000019
Patent Text Reader

Abstract

The present invention relates to a method for producing an alcohol-free antimicrobial moisturizing hand sanitizer comprising (i) a polymer-based nanoemulsion comprising one or more active compounds selected from cyanovirin-N (CV-N), cannabidiol (CBD) and palmitic acid (PA), and (ii) an aqueous gel-like moisturizing composition comprising a preservative such as xanthan gum, glycerol, and citric acid. The present invention further relates to the alcohol-free antimicrobial moisturizing hand sanitizer produced by the method of the present invention and the use of the hand sanitizer as an antimicrobial agent, in particular an antiviral agent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to a method for producing an alcohol-free antimicrobial moisturizing hand sanitizer comprising (i) a polymer-based nanoemulsion comprising one or more active compounds selected from cyanovirin-N (CV-N), cannabidiol (CBD) and palmitic acid (PA), and (ii) an aqueous gel-like moisturizing composition comprising a preservative such as xanthan gum, glycerol, and citric acid. The present invention further relates to the alcohol-free antimicrobial moisturizing hand sanitizer produced by the method of the present invention and the use of the hand sanitizer as an antimicrobial agent, in particular an antiviral agent. [Background technology]

[0002] 2. Background of the Invention Humanity continues to suffer from the unprecedented global pandemic of coronavirus disease-2019 (COVID-19), a highly contagious and deadly respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The virus is transmitted from person to person by direct contact with bodily fluids of infected individuals and through aerosols (fomites), mainly from coughing and sneezing. Recent studies have further shown that the virus can remain viable and externally transmissible for up to nine days on various surfaces (Jing et al., 2020). Wearing face masks and practicing good personal hand hygiene are paramount to curb the spread of the disease, and the World Health Organization (WHO) has recommended mitigation of both. WHO also strongly recommends the use of alcohol-based hand sanitizers (ABHS) as they are rapid in activity and have broad spectrum antimicrobial activity, including viral.

[0003] However, concerns have long been raised about the adverse health and safety hazards associated with the high alcohol content required for maximum activity. The dangers are due to the chemical properties of alcohols, which are highly flammable and evaporate easily even at room temperature (20-22 °C). The main concern is the fire hazard they pose, and that the vapours can easily cause an explosion if they mix with air and there is an ignition source in close proximity. These concentrations can also cause dizziness in poorly ventilated environments, as well as eye and skin irritation. According to the South African National Fire Protection Association (NFPA) classification of flammable and combustible liquids, alcohol is a class 1 flammable liquid (the highest class). Among the potential health hazards is acute alcohol poisoning, which can be life-threatening if ingested, mainly affecting children. It is worth mentioning that the alcohol in the drink (ethyl alcohol) is not necessarily the alcohol in the sanitizer, since isopropyl alcohol is also used, which is not suitable for ingestion.

[0004] Furthermore, the outermost layer of the skin is composed of various lipids that form a protective barrier together with the skin microbiome. Excessive and frequent use of alcohol-based sanitizers can dissolve and remove the lipid barrier and also degrade the skin microbiome. As a result, the skin becomes vulnerable, susceptible to secondary infections by other pathogens, and the skin becomes dry. Dry and dehydrated skin can lead to irritation, which is likely to cause itching, scaling, peeling or flaking, cracking, and gray / grey skin color. Removal of these barriers can also cause painful inflammation (swelling) and redness of the skin, increasing the likelihood of developing atopic dermatitis (eczema).

[0005] These risks and their potential harmful consequences call for research into the development of safer non-alcohol-based hand sanitizers, such as alcohol-free hand sanitizers (AFHS), that are safe for hands and are particularly effective against easily transmissible viruses such as SARS-CoV-2.

[0006] To date, various methods have been developed to prepare AFHS formulations for various personal hygiene habits. These techniques involve the use of benzalkonium chloride (BAC) or triclosan (TCS) as active antimicrobial agents, along with various thickeners, preservatives, and fragrances, for application in a number of pharmaceutical and personal care products, such as medicated soaps, hand sanitizers, deodorants, toothpastes, air fresheners, and other cosmetic products. However, concerns have also been raised regarding the safety of these antimicrobial agents, especially the safety of TCS, which is now considered an emerging contaminant. Summary of the Invention [Problem to be solved by the invention]

[0007] Thus, there is a need for hand sanitizers that contain effectively deliverable, naturally occurring compounds that have antimicrobial, and particularly antiviral, properties, and that are safe. [Means for solving the problem]

[0008] Summary of the Invention According to a first aspect of the present invention, there is provided a process for producing an alcohol-free antimicrobial moisturizing hand sanitizer, comprising the steps of: (i) co-dissolving at least one hydrophobic active compound selected from AI cannabidiol (CBD) and palmitic acid (PA) with at least one copolymer in a polar aprotic solvent; A.II. Adding a surfactant to form an organic phase; A.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer to form a nanoemulsion; and A.IV. Stabilizing the nanoemulsion by stirring or BI dissolving at least one copolymer in a polar aprotic solvent; B.II. Adding a surfactant to form an organic phase; B.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from cyanovirin-N (CV-N) to form a nanoemulsion; and B.IV. Stabilizing the nanoemulsion by stirring or co-dissolving at least one hydrophobic active compound selected from CI CBD, PA or both and at least one copolymer in a polar aprotic solvent; C.II. Adding a surfactant to form an organic phase; C.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from CV-N to form a nanoemulsion; and C.IV. Stabilizing the nanoemulsion by stirring producing a polymer-based nanoemulsion comprising: (ii) mixing the xanthan gum into the glycerol with stirring until it is completely dispersed in the DI glycerol; and D.II. Adding water and preservatives including citric acid and stirring to form an aqueous gel-like moisturizing composition. preparing an aqueous gel-like moisturizing composition comprising: (iii) mixing the stabilized nanoemulsion of step (i) with the aqueous gel-like moisturizing composition of step (ii) to form an alcohol-free antimicrobial moisturizing hand sanitizer; A process is provided that includes:

[0009] In one possible embodiment of the present invention, a process for producing an alcohol-free antimicrobial moisturizing hand sanitizer includes: (i) co-dissolving at least one hydrophobic active compound selected from AI cannabidiol (CBD) and palmitic acid (PA) and at least one copolymer in a polar aprotic solvent; A.II. Adding a surfactant to form an organic phase; A.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer to form a nanoemulsion; and A.IV. Stabilizing the nanoemulsion by stirring or BI dissolving at least one copolymer in a polar aprotic solvent; B.II. Adding a surfactant to form an organic phase; B.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from cyanovirin-N (CV-N) to form a nanoemulsion; and B.IV. Stabilizing the nanoemulsion by stirring or co-dissolving at least one hydrophobic active compound selected from CI CBD and PA and at least one copolymer in a polar aprotic solvent; C.II. Adding a surfactant to form an organic phase; C.III. Dispersing an organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from CV-N to form a nanoemulsion; and C.IV. Stabilizing the nanoemulsion by stirring and producing a polymer-based nanoemulsion comprising: (ii) mixing the xanthan gum into the glycerol with stirring until it is completely dispersed in the DI glycerol; and D.II. Adding water and a preservative selected from citric acid and stirring to form an aqueous gel-like moisturizing composition. and producing an aqueous gel-like moisturizing composition comprising: (iii) mixing the stabilized nanoemulsion of step (i) with the aqueous gel-like moisturizing composition of step (ii) to form an alcohol-free antimicrobial moisturizing hand sanitizer; It consists of:

[0010] At least one copolymer may be poly(lactic-co-glycolic acid) or PLGA, or alternatively any similar biocompatible and biodegradable polymer, including polylactic acid, polyglycolic acid, or poly-ε-caprolactone. Preferably, the copolymer is PLGA.

[0011] The polar aprotic solvent may consist of either ethanol or acetone, or may be a blend of ethanol and acetone. Preferably, the polar aprotic solvent is a co-solution of acetone / ethanol (3:1).

[0012] The surfactant may include any surfactant having a hydrophilic-lipophilic balance (HLB) value greater than 10. Preferably, the surfactant is polysorbate 80, also known as Tween 80®.

[0013] The at least one hydrophilic polymer may be any one or more of polyvinyl alcohol (PVA) and polyethylene glycol (PEG), such as PEG 4000. Preferably, the hydrophilic polymer is hydrolysed PVA.

[0014] Phosphate buffer (or PBS) may have a pH at 0° C. of about 7.2 to about 7.6, more preferably about 7.4.

[0015] In one embodiment of the present invention, the aqueous gel-like moisturizing composition may comprise or consist of a mixture of 0.0007 kg xanthan gum: 0.067 L glycerol: 0.005 kg citric acid: 1 L water (including ±5% variation of each amount).

[0016] In one embodiment of the present invention, the CV-N functionalized polymer-based nanoemulsion can comprise or consist of a mixture of 0.1-1 mg CV-N, 5-25 mg PLGA, 1-2 mL acetone / ethanol (3:1), 0.1-0.25 mL polysorbate 80 surfactant, 2-4 mL PBS, and 6-8 mL polyvinyl alcohol (1% w / v) (including any possible subranges or amounts within these ranges).

[0017] In another embodiment of the invention, the polymer-based nanoemulsion functionalized with CBD and / or PA can comprise or consist of a mixture of 0.5-2 mg CBD and / or 0.1-1 mg PA, 5-25 mg PLGA, 1-2 mL acetone / ethanol (3:1), 0.1-0.25 mL polysorbate 80 surfactant, 2-4 mL PBS, and 6-8 mL polyvinyl alcohol (1% w / v) (including any possible subranges or amounts within these ranges).

[0018] Further, in one particular embodiment of the present invention, the polymer-based nanoemulsion is mixed with an aqueous gel-like moisturizing composition in a ratio of about 1:99 (i.e., 1-10:90-99) to form an alcohol-free antimicrobial moisturizing hand sanitizer.

[0019] According to a second aspect of the present invention there is provided an alcohol-free antimicrobial moisturizing hand sanitizer manufactured according to the method of the present invention.

[0020] For example, the hand sanitizer may contain an active compound selected from any one of: (a) CV-N, CBD, or PA; (b) both CV-N and CBD, or both CBD and PA, or both CV-N and PA, or (c) all three of CV-N, CBD, and PA.

[0021] The hand sanitizer may be antimicrobial, including any one or more of an antibacterial, antiviral, or antifungal agent.

[0022] Polymer-based nanoemulsions are i. an inner nanoemulsion matrix composed of a polar aprotic solvent, at least one copolymer and a surfactant; ii. an outer shell comprising one or more hydrophilic polymers and a buffer; iii. one or more of the active compounds where if the active compound is hydrophobic, the active compound is contained within the inner nanoemulsion matrix, and if the active compound is hydrophilic, the active compound is contained within the outer shell.

[0023] Polymer-based nanoemulsions are Aa) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, a surfactant, and one or more active compounds selected from CBD and PA; Ab) an outer shell consisting of one or more hydrophilic polymers and a buffer; or Ba) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, and a surfactant; Bb) an outer shell consisting of one or more hydrophilic polymers, a buffer, and an active compound selected from CV-N; or Ca) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, a surfactant, and one or more active compounds selected from CBD and PA; Cb) an outer shell consisting of one or more hydrophilic polymers, a buffer, and an active compound selected from CV-N; It can consist of:

[0024] The outer shell may comprise, inter alia, an aqueous solution of a hydrophilic polymer such as any one or more of polyvinyl alcohol (PVA) and polyethylene glycol (PEG), e.g., PEG 4000. Preferably, the hydrophilic polymer is hydrolyzed PVA.

[0025] At least one copolymer may be poly(lactic-co-glycolic acid) or PLGA, or alternatively any similar biocompatible and biodegradable polymer, including polylactic acid, polyglycolic acid, or poly-ε-caprolactone. Preferably, the copolymer is PLGA.

[0026] The polar aprotic solvent may consist of either ethanol or acetone, or may be a blend of ethanol and acetone. Preferably, the polar aprotic solvent is a co-solution of acetone / ethanol (3:1).

[0027] The surfactant may include any surfactant having a hydrophilic-lipophilic balance (HLB) value greater than 10. Preferably, the surfactant is polysorbate 80, also known as Tween 80®.

[0028] Typically, the buffer is phosphate buffered saline (PBS).

[0029] The xanthan gum may be dispersed in glycerol.

[0030] According to a further aspect of the present invention there is provided a method for sanitizing hands and optionally surfaces using an alcohol-free antimicrobial moisturizing hand sanitizer according to the present invention.

[0031] According to a further aspect of the present invention there is provided a method for inhibiting microorganisms, including bacteria, viruses and fungi, particularly viruses, using an alcohol-free antimicrobial moisturizing hand sanitizer according to the present invention.

[0032] According to a further aspect of the present invention there is provided the use of an antimicrobial moisturising hand sanitiser according to the present invention in a method for hand hygiene and / or for inhibiting microorganisms including bacteria, viruses and fungi, in particular viruses.

[0033] The virus may be any one or more of HIV-1, or a coronavirus, including SARS-CoV-2 or MERS-CoV.

[0034] BRIEF DESCRIPTION OF THE DRAWINGS The invention will now be further described, by way of example only, with reference to the accompanying drawings, in which: [Brief description of the drawings]

[0035] [Figure 1] 1 shows a graphical representation of an alternative nanoemulsion delivery system solution incorporating any one or more of the active compounds CV-N, CBD and PA, including their incorporation sites in the nanoemulsion delivery system. [Diagram 2] 1 shows droplet size and size distribution of a control nanoemulsion (i.e., no added active compound). [Diagram 3]Shows the size and distribution of BSA (A) and CV-N nanoemulsions (B) in water. [Figure 4] 1 shows a BSA solution treated with CV-N nanoemulsion. [Diagram 5] 1 shows the size distribution of CBD nanoemulsions. [Figure 6] Showing the antiviral activity of CBD nanoemulsion sanitizer against SARS-CoV-2 pseudovirus. [Figure 7] 1 shows droplet size and size distribution of PA nanoemulsions. [Figure 8] The results of the visual scores for skin irritation are shown. [Figure 9] Shown are the erythema results of a skin irritation chromameter. [Figure 10] Indicates the maximum skin irritation value. [Figure 11] 1 shows a conceptual design for the manufacture of a nanoemulsion hand sanitizer. [Figure 12] Cytotoxicity assay in 96-well plates. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] Detailed Description of the Invention The present invention relates to a method for producing an alcohol-free antimicrobial moisturizing hand sanitizer comprising (i) a polymer-based nanoemulsion comprising one or more active compounds selected from cyanovirin-N (CV-N), cannabidiol (CBD) and palmitic acid (PA), and (ii) an aqueous gel-like moisturizing composition comprising a preservative such as xanthan gum, glycerol, and citric acid. The present invention further relates to the alcohol-free antimicrobial moisturizing hand sanitizer produced by the method of the present invention and the use of the hand sanitizer as an antimicrobial agent, in particular an antiviral agent.

[0037] The following description of the invention is provided as an enabling teaching, illustrating the principles of the invention, and is not intended to limit the scope of the invention. It will be understood that changes can be made to the illustrated and described embodiments while still achieving the beneficial results of the invention. It will further be understood that some of the benefits of the invention can be achieved by selecting some of the features of the invention without utilizing other features. Thus, those skilled in the art will recognize that modifications and adaptations to the invention are possible, may be desirable in certain circumstances, and are part of the invention.

[0038] The applicant has developed a novel alcohol-free hand sanitizer technology that contains safe, naturally occurring antimicrobial compounds embedded in a polymer-based viscous nanoemulsion system with moisturizing effects on the hands as an alternative to alcohol-based hand sanitizers (ABHS). The active antimicrobial compounds of the technology include: i) Cyanovirin-N (CV-N), a lectin (protein) of natural origin with broad-spectrum antiviral activity; ii) cannabidiol (CBD), a phytocannabinoid molecule extracted from the cannabis plant with multifunctional uses and numerous health benefits; and iii) Palmitic acid (PA), a saturated fatty acid known to be a potent antimicrobial agent. Any one or more of the following is included.

[0039] Thus, an aspect of the present invention is a) a delivery system containing one or more active compounds selected from CV-N, CBD, and PA; b) an aqueous gel-like moisturizing composition composed of xanthan gum and glycerol, with citric acid as a preservative; with an alcohol-free nanoemulsion-based antimicrobial moisturizing hand sanitizer containing

[0040] A further aspect of the present invention relates to a manufacturing process for the production of an alcohol-free nanoemulsion based antimicrobial moisturizing hand sanitizer.

[0041] Each of the active compounds used in the present invention exhibits different characteristics with respect to speed, duration and spectrum of activity against viruses, pathogens and bacteria, and the combination of these characteristics therefore provides the present invention with unique properties for improved multifunctional antimicrobial activity against virulent bacteria, viruses and other pathogens.

[0042] In particular, the active compounds CV-N, CBD and PA have been selected for inclusion in the present invention due to their characteristics as described below. · CV-N: Provides a broad spectrum of antiviral activity against enveloped viruses, including inhibition of HIV and SARS-CoV-2. · CBD: Provides an extra layer of protection against resistant bacteria and other harmful pathogens. · PA: Acts as an active supplement needed to maintain and restore the skin's natural barrier function against drug resistance and harmful pathogens.

[0043] Additionally, the polymer-based nanoemulsion antimicrobial delivery system and natural gum-based gel topical dosage form provide a balance of antimicrobial efficacy while improving the condition of the user's skin over extended periods of use and minimizing dry time to avoid discomfort to the user's hands associated with prolonged "wetness" of the skin surface.

[0044] Lectins are a cluster of proteins that are naturally produced mainly in plants, some dairy products, and eggs. Their structural composition is rich in carbohydrates and they have high binding specificity for sugar groups in either cellular or unicellular organisms, leading to agglutination. These properties are desirable for antimicrobial activity, and Mitchell et al. (2007) showed that they have similar carbohydrate affinity for the glycoproteins of enveloped viruses, leading to viral disintegration.

[0045] Cyanovirin-N (CV-N) has also been shown to have these properties against enveloped viruses with class 1 fusion proteins, such as the gp120 / gp41 fusion glycoprotein of human immunodeficiency virus (HIV), and inhibits HIV virus-mediated cell infection. The broad-spectrum antiviral activity of CV-N is likely to inhibit viral infection by SARS-CoV-2, as this is also an enveloped virus with a class 1 fusion protein.

[0046] Cannabidiol (CBD) has become exponentially more attractive for its numerous health benefits due to its ability to induce and regulate various cellular functions beneficial to the body. Recent studies have also shown that CBD has strong antimicrobial activity against gram-positive bacteria (Wassmann et al., 2020; Martinenghi et al., 2020). CBD has been included in the present invention by the applicant to act as a helper compound against resistant bacteria and as an additional layer of protection against other pathogens.

[0047] Palmitic acid (PA) is a naturally occurring saturated fatty acid and a precursor of many endogenous and exogenous phospholipids. PA is a precursor of ceramides that form the skin lipid barrier and is widely used in personal care products as a surfactant or emulsifier. Several saturated fatty acids, including PA, have been shown to have antibacterial activity against a wide range of Gram-positive bacteria and some fungi (Nguyen et al., 2016).

[0048] Xanthan gum has attracted great interest as a good gelling agent for preparing aqueous gels with a pleasant cool skin feel upon application. Xanthan gum has the ability to form highly viscous solutions at low concentrations and has been shown to be stable at various temperatures and over a wide pH range. Furthermore, it is compatible with all ingredients present in skin care products, such as salts, metal cations, surfactants, or bioactive compounds. Due to such excellent properties, xanthan gum has found numerous applications in oral and topical formulations, cosmetics, and foods as a suspending or stabilizing agent, thickener, emulsifier, film former, gelling agent, and release control agent in hydrophilic matrix formulations (Abdulsalam et al. 2018, Pawan et al., 2004).

[0049] The applicant's technology presents a much larger opportunity beyond the current COVID-19 pandemic. It presents a rapid, uncomplicated and cost-effective process methodology for producing a safe and effective alcohol-free hand sanitizer. It employs the use of naturally occurring antimicrobial actives with a broad spectrum of activity, posing none of the safety and health hazards associated with ABHS. The applicant's technology provides a dermatologically safe moisturizing product suitable for repeated use while maintaining the skin's microflora and excess precursor lipids for epidermal skin lipids (i.e., ceramides) and sebaceous gland skin lipids (i.e., triglycerides). Furthermore, it is an alternative for anti-alcohol users, whether individuals due to specific phobias or groups / populations due to religious beliefs.

[0050] The following illustrative examples are provided as enabling teachings and illustrate the principles of the present invention, and are not intended to limit the scope of the present invention. It will be understood that changes can be made to the depicted and described embodiments while still achieving the beneficial results of the present invention. It will further be understood that some of the benefits of the present invention can be achieved by selecting some of the features of the present invention without utilizing other features. Thus, those skilled in the art will recognize that modifications and adaptations to the present invention are possible and may be desirable in certain circumstances and are part of the present invention. EXAMPLES

[0051] Working Example 1. Goals and Objectives The primary objective of this study is to develop a safe and stable aqueous delivery system incorporating any one or more of cyanovirin-N (CV-N), cannabidiol (CBD) and palmitic acid (PA) as active compounds. Figure 1 shows a graphical representation of alternative nanoemulsion delivery system solutions incorporating any one or more of active compounds CV-N, CBD and PA, including their incorporation sites in the nanoemulsion delivery system. For example, the nanoemulsion delivery system may contain only CV-N, CBD or PA, or all of CV-N, CBD and PA, or only CV-N and CBD, only CBD and PA, or only CV-N and PA. These nanoemulsion delivery systems were then infused with a viscosity builder solution of xanthan gum and glycerol to produce a safe and inexpensive lubricating gel-based hand sanitizer.

[0052] 1.1. Specific Objectives The specific objectives are: Synthesis of nanoemulsions incorporating CV-N Synthesis of CBD-incorporated nanoemulsions Synthesis of nanoemulsions incorporating PA Synthesis of xanthan gum gel solution Synthesis of nanoemulsion sanitizer (injection of nanoemulsion into gel solution) Physicochemical characterization and stability studies Antiviral activity of nanoemulsion sanitizers against pseudotyped viruses in vitro In vitro cytotoxicity studies Skin irritation patch test Includes:

[0053] 2. Materials and Methods 2.1. Materials for nanoemulsion synthesis Cannabidiol was supplied by Tautomer (Pty) Ltd and purchased from REGENT Pharmaceuticals, UK. Cyanovirin-N was supplied by the NextGen Health Cluster of CSIR and palmitic acid was purchased from DB Fine Chemicals, South Africa. Solvents were purchased from Sigma and included ethanol, acetone, acetonitrile, dimethylsulfoxide (DMSO), ethyl acetate, dichloromethane (DCM) and oleic acid. Polyvinyl alcohol (PVA) (87-89 hydrolysis / Mw=13000-23000), stearic acid and phosphate buffered saline (PBS-pH 7.4) reagents were also obtained from Sigma Aldrich, South Africa.

[0054] 2.2.Physicochemical analysis equipment A Malvern Zetasizer Nano Series ZS (DLS) was used to determine hydrodynamic size, size distribution and stability. An Acsen pH meter from Lasec was used to monitor the pH of the emulsions and a Shimadzu SIL-20AXR / 20ACRXR prominence High Pressure Liquid Chromatography (HPLC) was used for qualitative analysis (to check the integrity of the active substance after formulation and during storage).

[0055] 2.3.Cell culture materials Human lung cancer cells A549 were a gift from the Scholefield laboratory (CSIR). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing L-glutamine and sodium pyruvate obtained from Life Technologies, NY (USA). Culture medium was supplemented with 10% fetal calf serum (FCS) and trypsin-EDTA 0.25% solution was used to detach adherent cells, both purchased from Thermo Fischer Scientific, Johannesburg (South Africa). MTT colorimetric cell proliferation assay was used to investigate toxicity and was purchased from Sigma (Roche, Mannheim, Germany).

[0056] 2.4. Method 2.4.1. Synthesis of CV-N nanoemulsion Briefly, the nanoemulsion system functionalized with CV-N was prepared as follows: CV-N stock solution was prepared by dissolving 0.1 mg in 1 mL of PBS (pH 7.4) solution. The organic phase (internal phase) was prepared by dissolving PLGA in 2 mL of acetone / ethanol (3:1) co-solution followed by the addition of 10–20 μl (2 drops) of Tween 80 surfactant. The polar phase (continuous phase) was prepared by mixing 4.5 mL of a buffer solution of PBS (pH 7.4) with 13.5 mL of the hydrolyzed hydrophilic polymer polyvinyl alcohol (1% w / v PVA). The CV-N stock solution (100 μL) was added to the continuous phase under stirring (400 rpm) at room temperature (± 21 °C).

[0057] Nanoemulsions were synthesized by adding the organic phase to the continuous phase under stirring, and spontaneous precipitation reactions led to the self-assembly of stable nanoemulsions through nucleation. The nanoemulsions were then stirred in a fume hood for 2 hours to allow the solvent to evaporate. A control nanoemulsion without the addition of lectin was also prepared following the exact synthesis method described above.

[0058] 2.4.2. Synthesis of CBD nanoemulsion The organic phase was prepared by co-dissolving PLGA and CBD (10 mg each) in 2 mL of acetone / ethanol (3:1) co-solution followed by the addition of 10–20 μl (2 drops) of Tween 80. The polar phase was prepared by mixing 4.5 mL of PBS solution (pH 7.4) and 13.5 mL of polyvinyl alcohol (1% w / v PVA). To form a nanoemulsion, the organic phase was added to the continuous phase under stirring. Spontaneous precipitation resulted in a stable nanoemulsion encapsulating CBD, which was stirred for 2 h in a fume hood to allow the solvent to evaporate.

[0059] 2.4.3. Synthesis of PA nanoemulsion The organic phase was prepared by dissolving 10 mg of PLGA and 1 mg of PA in 2 mL of a co-solution of acetone / ethanol (3:1), followed by the addition of 10–20 μl (2 drops) of Tween 80. The continuous polar phase was prepared by mixing 4.5 mL of PBS pH 7.4 with the hydrophilic polymer polyvinyl alcohol (13.5 mL). To form a nanoemulsion, the organic phase was added to the continuous phase under stirring, and self-assembly of PLGA / PA nanodroplets occurred by spontaneous precipitation. The system was then stirred in a fume hood for 2 h to allow the solvent to evaporate.

[0060] 2.4.4. Synthesis of xanthan gum / glycerol solution Various gums are hygroscopic and tend to hydrate on direct contact with water, often leading to the formation of gumballs or clumps of dry powder that water cannot penetrate. To overcome this, glycerol was used to disperse the gum powder to minimize hydration prior to gel formation. Thus, in a typical procedure, various amounts of xanthan gum, ranging from 0.025 g to 0.3 g, were accurately weighed into a 250 mL Erlenmeyer flask containing 10 mL of glycerol. The mixture was stirred slowly magnetically to allow complete dispersion of the xanthan gum. To this flask, 150 mL of deionized water at 60 °C was added with vigorous stirring at 500 rpm to remove air bubbles and gumballs during gel formation. The gels were kept under vigorous stirring for 30 min, and the final volume of the gels ranged from 155 to 160 mL. The compositions of the gels prepared are summarized in Table 1.

[0061] [Table 1]

[0062] 2.4.5. Synthesis of Sanitizers A final concentration of 10% (v / v) of nanoemulsion was injected into the gel to form all sanitizers. Each sanitizer was prepared by adding 1 mL of nanoemulsion to 9 mL of gel solution with moderate stirring at room temperature.

[0063] 2.4.6. Hydrodynamic size and size distribution The hydrodynamic size, size distribution and stability of the nanoemulsions were determined by dynamic light scattering (DLS) technique using a Malvern Zetasizer Nano ZS. DLS instruments measure Brownian motion, which is the random movement (fluctuation) of submicron particles in solution, to determine hydrodynamic size.

[0064] Briefly, a laser beam is used to illuminate the sample solution, the incident laser beam is scattered in all directions, and the intensity is measured by a detector. The stability of submicron particles can also be determined over time through continuous sample analysis by DLS. Samples for analysis were prepared in deionized water and diluted 300-400 times, and disposable Zetasizer cuvettes were used for analysis.

[0065] 2.4.7. Stability Emulsion stability is by far the most important property to consider and achieve, since it is at this stage that most failures occur. This is the ability of a nanoemulsion to maintain its essential physicochemical properties (e.g. size and distribution) over time and to be unaffected by most environmental changes (i.e. temperature). To achieve good stability, key considerations such as surfactant properties and solvent thermodynamics are paramount.

[0066] Breakdown (instability) of an emulsion can be due to phase separation (1), Ostwald ripening (2), flocculation (3) or phase inversion (4). Instability can be observed with the naked eye by precipitation or settling, but can also be slower and take longer.

[0067] In this study, the stability of the emulsion and sanitizer was investigated through sequential analysis of the size and size distribution of both systems. Samples were prepared using a Malvern Zetasizer Nano Series ZS by adding 100 μL of sample to 5 mL of deionized water.

[0068] 2.4.8. In vitro inhibition assay The inhibitory activity of CV-N, CBD, PA and their combinations incorporated into the nanoemulsion delivery system was tested in a TZM-bl neutralization assay, which mimics the inhibition of free viral particle infection of cells. Briefly, the TZM-bl neutralization assay was performed in duplicate by preparing a dilution series of inhibitors in 100 μL of growth medium (DMEM) containing 10% fetal bovine serum (FBS) in a 96-well plate. After this, 100 TCID 50 of pseudotyped virus was added to 50 μL of growth medium and incubated for 1 h at 37 °C. Then, 1 × 10 5 100 μL of TZM-bl cells at a concentration of 100 cells / mL are added to each well and incubated for 48 hours at 37° C. Infection can be assessed by measuring the activity of firefly luciferase.

[0069] Titers are defined as the inhibitor dilution (ID ) that causes a 50% decrease in relative luminescence units (RLU) compared to virus controls (wells without inhibitors) after subtracting the background (wells without both virus and inhibitors). 50 Luciferase assays were performed using the Bright-Gloluciferase Assay Kit (Promega, USA) according to the manufacturer's instructions, and luciferase activity was expressed using relative luciferase units (RLU).

[0070] 2.4.9. In vitro cytotoxicity assays Cells were grown in DMEM / F12 penicillin (50 μg / ml), streptomycin (50 μg / ml), and neomycin (100 μg / ml) and 10% heat-inactivated fetal calf serum (FCS) at 0.5–5 × 10 6 Cells were maintained at a confluency of 5 × 10 cells / ml. Cells were incubated at 37 °C in a 5% CO2(g) humidified incubator and passaged 2-3 times per week. Cell viability was determined by using a trypan blue exclusion test. Cells were cultured at 5 × 10 cells / ml using 100 μl per well. 4Cells were seeded in 96-well plates at a density of 100 μl cells / ml and incubated for 48 hours before treatment. Cells were incubated with 100 μl of different microemulsions at different concentrations as shown in Figure 12. All test samples were diluted in complete medium without antibiotics. Control samples: Cannabidiol and palmitic acid were solubilized in DMSO (up to 2% v / v) before dilution in culture medium. Cyanovirin-N was prepared in PBS (pH 7.4) and further diluted in culture medium without DMSO.

[0071] The MTT assay was performed according to the manufacturer's instructions. In summary, this non-radioactive colorimetric assay system using MTT was first described by Mosmann, T (1983) and improved by several other investigators in the following years. The MTT assay is used to measure the metabolic activity of cells as an indicator of cell viability, proliferation and cytotoxicity. This colorimetric assay is based on the reduction of a yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT) to purple formazan crystals by metabolically active cells. Viable cells contain the NAD(P)H-dependent oxidoreductase enzyme that reduces MTT to formazan. The insoluble formazan crystals are dissolved using a solubilizing solution and the resulting colored solution is quantified by measuring the absorbance at 500-600 nanometers using a multiwell spectrophotometer. After 24 hours of incubation with the test compounds, MTT dissolved in PBS pH 7.4 (100 μg / well) was added to the cells and incubated for 4 hours at 37°C. Unconverted MTT was carefully removed by aspiration and the formed formazan crystals were dissolved in 100 μl of solubilization solution. The absorbance was read at 550 nm with a 650 nm reference filter. The viability percentage was calculated by the absorbance intensity of the cells incubated with the microemulsion as a function of that of the untreated cells. Three independent experiments were performed and each compound was tested in triplicate wells.

[0072] 2.4.10. Skin irritation The aim of this study was to determine the skin irritation potential of the nanoemulsion hand sanitizer product of the present invention. The study was carried out in accordance with internationally recognized Good Clinical Practice Guidelines. Permission to conduct the study was secured under protocol approval of the Research, Ethics and Publications Committee of Sefako Makgatho Health Sciences University for project MREC / H / 48 / 2014:CR. Recruitment for the study began 2 weeks prior to the start of the study and, according to the study requirements, approximately 25 panelists were recruited and the study started with a test panel of 20. Potential panelists attended a series of study information sessions held in the week prior to the study. Panelists were orally briefed and received the study description, informed consent form (and a colored copy of the latter).

[0073] Panelists were given set appointments at specific times throughout the study. Unless otherwise stated in the synopsis, 20 adult female volunteers were used, 5 of whom had sensitive skin (determined from the subject enrolment questionnaire). Signed informed consent was obtained from all subjects. Subjects with a history of clinical skin abnormalities or taking or using medications that may affect the study results by mediating an inflammatory response were excluded. 20 adult female volunteers were used, 5 of whom had sensitive skin. Signed informed consent was obtained from all subjects.

[0074] Briefly, the study procedure was as follows; control and product were applied to the inner forearm of each volunteer in a randomized blinded pattern at zero hours and repeated at the same location at 24 hours. A measured amount of control or product strip was placed into each chamber, and the chamber was attached to the forearm. Products were tested using specially designed aluminum fin chambers on Scanpore® tape for occluded sites, or modified Hilltop chambers for non-occluded sites. Patches were observed at 0, 24, 48, 72 and 96 hours after application. The patch area was covered with the chamber for the first 2 x 23 hours, after which the chamber was removed.

[0075] The protocol uses a 1% sodium lauryl sulfate (SLS) solution as a positive control and deionized water as a negative control. A measured amount of 0.02 ml of sodium lauryl sulfate and deionized water was applied. The following visual scoring system was used to classify the reactions. The color evaluation was performed in a "double-blind" manner in two ways: visual score; 0=no reaction, 1=slight erythema, 2=strong erythema limited to the area of ​​direct contact, and 3=strong erythema extending beyond the area of ​​contact. The irritation level is classified by the laboratory based on the visual score as follows: Product Mean Visual Score + SD>1.5 - product is irritating. Product Mean Visual Score + SD<=1.5 and >negative control - product is likely to be a low irritant. Product Mean Visual Score + SD<=negative control - product is non-irritating. Second, color is measured on a red / green axis, a * The values ​​are from instrumental scores using a Minolta Cr400 colorimeter.

[0076] 3. Results and Discussion 3.1. Nanoemulsion-control system 3.1.1. Discussion of physicochemical results The nanoemulsion system was successfully developed by a single oil-in-water (O / W) nanoemulsion via rapid nanoprecipitation technique. The physical properties of the nanoemulsions in terms of size (diameter, nm) and distribution were determined by DLS analysis.

[0077] FIG. 2 shows a graphical representation of the control nanoemulsion properties, the average droplet size was 105.7 nm with a uniform size distribution.

[0078] pH and physical properties were used as parameters to study the stability (Table 3). The control nanoemulsion had an initial pH of 5.71 (±0.03) and was stored at room temperature (±21°C) with properties unchanged over a period of 5 months. A size reduction of 1.8 nm was expected (≦7%) and was the result of solvent evaporation.

[0079] [Table 2]

[0080] 3.2. Cyanovirin-N Sanitizer 3.2.1. Discussion of physicochemical results CV-N was successfully functionalized onto the surface droplets of the nanoemulsion system, with a suitable average size of 155.4 nm and a size distribution just below the acceptable range (PDI ≤ 0.3). The increase in size is the first parameter observed in determining success, and the results in Table 4 suggest successful functionalization. To motivate the use of size as a determining factor, a stock solution of CV-N was analyzed, with 60-70% of the size ranging between 25-50 nm. However, for confirmation, a qualitative analysis by high-resolution transmission electron microscopy (TEM) is required and recommended. Stability was investigated and determined by a similar method used for the control nanoemulsion and described above.

[0081] [Table 3]

[0082] These results show a larger size reduction of at least 17%, exceeding the 7% threshold. The pH was within the acceptable range after 5 months. The functionalization process occurs mainly by occlusion onto the outer surfactant layer formed by the hydrophilic polymer. The occlusion process is a non-chemical reaction and the droplets are semi-solids that continuously move and collide by Brownian motion. The consistent collision of the droplets can result in two outcomes; the first is the loosening and subsequent removal of some CVN from the droplet surface, and / or the second is that the protein is further internalized (pushed in) due to the droplets being semi-solid. Neither possible outcome of the protein degrades or affects its functionality, the protein remains intact within the nanoemulsion and continues to function as intended, and its integrity was confirmed by HPLC analysis before and after synthesis.

[0083] In addition to confirmation by HPLC analysis, we designed a study to test our hypothesis and preliminary results support the mechanism we propose for the observed size reduction. As specified in the project proposal, our strategy was to develop a delivery system with high binding affinity for viral surface proteins. The synthesis of nanoemulsions aimed to non-chemically functionalize (attach) CV-N by occlusion to the droplet surface, which we achieved. In this study, we investigated the affinity of proteins for binding to the surface of functionalized droplets in nanoemulsions and used size as the determining parameter.

[0084] Proteins are long-chain polypeptides synthesized from hydrophobic and hydrophilic amino acids, and the folding arrangement is responsible for their solubility in water. Non-polar (hydrophobic) amino acids form the core (interior) and polar (hydrophilic) amino acids form the outer surface, resulting in quaternary proteins with a spherical (round) three-dimensional shape. Employing the use of solutions of various concentrations of a 66.5 kDa protein; bovine serum albumin (BSA), analyzed by DLS, the size (diameter) of a single quaternary spherical structure was approximately ±5 nm (Figure 3A), a result also confirmed in the literature. The size distribution of proteins changes in water (5 to 360 nm), due to the lack of buffer ions as found in blood, and therefore the clustering of protein molecules to form aggregates.

[0085] The BSA solution was then treated with a few drops (1-5 drops) of the CV-N nanoemulsion and immediately analyzed. The initial size of the droplets in the nanoemulsion was approximately 141.7 nm with a uniform size distribution. This can be seen in Figure 3B above. The size and size distribution of the treated BSA solution rapidly and significantly improved, with the droplet size increasing by at least ±8 nm. Figure 4 below shows the increase in size and uniform size distribution in just a few seconds. Furthermore, this study was performed in duplicate and the results were found to be identical.

[0086] 3.2.2. In Vitro Inhibition Assay of HIV-1 Pseudotyped Viruses The antiviral activity of CV-N nanoemulsion sanitizer was demonstrated in a TZM-bl neutralization assay using 100 TCID50, and successful inhibition was observed. Table 5 shows the inhibition profile of the sanitizer from high to low concentrations of CV-N.

[0087] Interestingly, the reported IC50 of CV-N with 100 TCID50 infection ranges from 2 to 31 nM (22 to 340 μg), meaning that at least 22 μg of CVN must be present in the solution to inhibit 50% of the virus. Our initial CV-N concentration in the nanoemulsion sanitizer was 0.5 μg / mL, and then serial dilutions of the sample preparations were made such that 0.025 μg (in 50 μL of sanitizer) was the total CV-N concentration used in well A. The average virus control (VC) was used to calculate the inhibition percentage.

[0088] [Table 4]

[0089] 3.3.Cannabidiol Sanitizer 3.3.1. Discussion of physicochemical results Various concentrations of CBD incorporated into the nanoemulsions were investigated, and three nanoemulsions were synthesized with CBD contents of 2, 10, and 20 mg. The hydrodynamic size and size distribution of the nanoemulsion systems with various concentrations were 114.7 nm, 108 nm, and 158.3 nm, respectively (see Figure 5).

[0090] Although it seems unusual that the lower concentration (2 mg) has a slightly larger size than the medium concentration (10 mg), the results are clear. In detail, similar molecules (hydrophobic-hydrophobic) tend to aggregate when introduced into an unfavorable environment (polar), and the concentration determines their arrangement. The arrangement of the lower concentrations is usually irregular compared to the slightly higher concentrations, and this phenomenon can be explained by the principle of critical micelle concentration (CMC). Compared to the encapsulating polymer matrix, CBD is more hydrophobic and smaller. This in turn means that the CBD molecules will precipitate faster compared to the polymer. As a result, CBD will form small aggregates, which are surrounded by the polymer, and then the hydrophilic surfactant polymer will encase the micelles.

[0091] In the absence of structural support from the inside, this would result in the formation of irregular shapes, whereas the dense core would maintain its morphological integrity. Also, using the same concentration of polymer and a 1:1 ratio (polymer / drug) resulted in ideal properties for CBD in this nanoemulsion system. The highest CBD concentration that can be incorporated into a 10 mg polymer core is 10 mg.

[0092] pH and physical properties were also used as parameters to investigate the stability (Table 6). The initial pH of the nanoemulsion was 6.50 (±0.03) and was stored at room temperature (±21°C) and well characterized over 5 months. A size increase of at least 5 nm was observed (~5%). However, the improved size distribution suggests good stability.

[0093] [Table 5]

[0094] 3.3.2. In Vitro Inhibition Assay of HIV-1 Pseudotyped Viruses The antiviral activity of CBD was also demonstrated in the TZM-bl neutralization assay, achieving successful inhibition of cell infection of the pseudotyped virus, which can be observed in Table 7.

[0095] Table 7 below shows the initial virus concentrations, including controls (no virus), and the CBD concentrations used to achieve the inhibitory activity of the sanitizer. The initial CBD concentrations (A, B, and C) showed greater than 90% inhibition (LD90), with the LD50 achieved in well D at a CBD concentration of approximately 3.70 μg.

[0096] [Table 6]

[0097] 3.3.3. SARS-CoV-2 and MERS-CoV pseudotyped virus inhibition assays We demonstrated the antiviral activity of CBD emulsion in a TZM-bl neutralization assay, where successful inhibition of both SARS-CoV-2 and MERS-CoV pseudotyped viruses was achieved (Figure 6).

[0098] 3.4. Palmitic acid sanitizer 3.4.1. Discussion of physicochemical results As shown in Figure 7 below, a nanoemulsion system incorporating palmitic acid was successfully developed and had desirable size and size distribution.

[0099] pH and physical properties were also used as parameters to investigate the stability (Table 8). The initial pH of the nanoemulsion was 6.54 (±0.03) and increased slightly thereafter. However, the improved size distribution suggested good stability. The nanoemulsion was stored at room temperature (±21°C) and was well characterized over a period of 5 months. A size reduction of at least 33 nm was observed (~21%), improving stability, but further investigation is needed to identify the cause.

[0100] [Table 7]

[0101] 3.4.2. In Vitro Inhibition Assay of HIV-1 Pseudotyped Viruses The antiviral activity of the PA sanitizer was demonstrated using a TZM-bl neutralization assay, and successful inhibition of cell infection of the pseudotyped viruses was observed (Table 9).

[0102] [Table 8]

[0103] 4. In Vitro Biological Assays Cytotoxicity assays in A549 cells showed significant toxicity with CV-N and CBD controls (results not shown), and the MTT assay was used to measure cellular metabolic activity as an indicator of cell viability and proliferation.

[0104] The highest concentration of the control nanoemulsion showed no toxicity and the average cell viability was over 85%. Pure CBD showed significant toxicity, whereas the CBD nanoemulsion showed no toxicity and significantly improved cell proliferation. The CV-N nanoemulsion showed slight toxicity at higher concentrations. However, the highest CV-N concentration used for the nanoemulsion sanitizer was 0.025 μg, thus much lower compared to the lowest concentration in this toxicity study (1.56 μg) and therefore considered safe.

[0105] 5.Skin irritation All panelists attended their daily visits unless otherwise stated in the synopsis. There were no adverse events during the study unless noted in the synopsis. In case of adverse events, a report will be submitted to the Research and Ethics Committee of Sefako Makgatho Health Sciences University. Data was collected at each visit according to the methods described above. The products were tested on the volar forearms of 20 panelists. A graphical representation of the results shows data for the products, negative control (deionized water) and positive control (1% SLS).

[0106] 5.1. Visual score The maximum irritation (calculated by the mean visual score + 1 standard deviation of the visual score) of the products and controls is shown in the table below. The irritation limit of the visual score + 1 standard deviation (SD) is 1.5 on a 0-3 scale.

[0107] 5.2. Colorimeter Saturation at each test site compared to baselinea * The change in value is calculated as follows: Delta A * = (product a at time t) * -Product a at time 0 * )-(untreated a at time t * - Untreated at time 0a * )

[0108] Delta a for all panelists for a given product at a given time * The values ​​were averaged and plotted in the attached graph. * The value data pattern supported the visual erythema assessment scores (provided in FIG. 9).

[0109] [Table 9]

[0110] It was confirmed and concluded that no adverse events were observed in this study. Figure 10 shows a graphical summary of the study results.

[0111] 6. Manufacturing method 6.1. Sanitizer preparation steps The synthesis process of the nanoemulsion hand sanitizer described herein can be divided into five preparation steps, including three stages of nanoemulsion preparation, a gelation stage, and finally a fusion stage. The nanoemulsion stages include the preparation of the internal phase (P1) and the preparation of the continuous phase (P2), followed by the formation of the nanoemulsion (P3).

[0112] 6.2. Steps Preparation and Cost Calculation (1~3) The preparation of the organic phase includes three liquid streams for the solvent solution, one solid stream for the polymer, and a reactor for solvation. An additional branched solid stream with a branch to the solvation reactor (CBD and / or PA) and another branch to the protein reactor (CV-N) is required for the active compound (drug). Table 11 below shows the amount of raw materials required to produce 1 L of solvent solution.

[0113] [Table 10]

[0114] The continuous phase is composed of a mixture solution of PBS and PVA (1:3). Estimated amounts of raw materials needed to prepare 1 L for both the PBS solution (Table 12) and the PVA solution (Table 13) are seen below.

[0115] [Table 11]

[0116] [Table 12]

[0117] Stage 3 is the nanoemulsion formation process, which involves adding the internal phase to the continuous phase with stirring, and the amounts for the synthesis process of 1 L of nanoemulsion are shown in Table 14.

[0118] [Table 13]

[0119] 6.3. Phase 4 Preparation and Cost Calculation The gelling step is the preparation of a viscous mixture composed of xanthan gum, glycerol and citric acid in water.

[0120] [Table 14]

[0121] 6.4. Phase 5 Preparation and Cost Calculation The fusion stage is the final process where the nanoemulsion is added to the viscous gel to produce the nanoemulsion hand sanitizer, Table 16 below shows all the streams to produce 1L of nanoemulsion hand sanitizer.

[0122] [Table 15]

[0123] [Table 16]

[0124] 7. Conclusion One of the currently most recommended non-pharmaceutical strategies consists in using 70-95% alcoholic sanitizers to control infections caused by coronaviruses. The frequent use of such solutions with a high content of alcohol (ethyl alcohol, isopropanol or n-propanol) has harmful effects on humans, often children under the age of 12. One of the expected long-term effects is the depletion of the skin's first line of defense against infection (i.e. the microbiome and lipid layer), thus creating a freeway for microbial attack.

[0125] It seems important that non-alcoholic hand sanitizers are needed to reduce infection by SARS-CoV-2 while preventing exposure to other microbial species that can penetrate the skin if the microbiome is damaged by alcohol-based sanitizers.

[0126] The applicant has therefore succeeded in developing a non-alcoholic, aqueous antimicrobial hand sanitizer containing a safe polymeric compound with an amphiphilic fatty acid incorporating one or more active substances selected from cyanovirin-N, cannabidiol and palmitic acid, which, used individually or in combination, have shown strong binding to the pseudotyped SARS-CoV-2 virus, resulting in its complete inhibition or deactivation at relatively low concentrations.

[0127] The system is shown to be safe according to in vitro cytotoxicity tests. A small-scale irritation patch test was performed on 20 human skin by an accredited laboratory with non-irritating results. The system is cost-effective and easy to scale up.

[0128] References Bergamaschi MM, Costa Queiroz RH, Crippa JAS and Zuardi AW. 2011. Safety and side effects of Cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6: 1-13 Bruni N, Pepa CD, Oliaro-Bosso S, Pessione E et al. 2018. Cannabinoid delivery systems for pain and inflammation treatment. Molecules, 23: 2478; doi:10.3390 / molecules23102478 Choi et al. 2008. Cannabidiol Induces Cytotoxicity and Cell Death via Apoptotic Pathway in Cancer Cell Lines. Biomolecules & Therapeutics, 16: 87-94. Dey B., Lerner D. L., Lusso P., Boyd M. R., Elder J. H. and Berger E. A. 2000. Multiple antiviral activities of Cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 Interaction with CD4 and co-receptor and inhibition of diverse enveloped viruses. J. Virol., 74: 4562-4569. Dixit, A., Pandey, P., Mahajan, R. and Dhasmana, D.C. 2014. Alcohol based hand sanitisers: Assurance and apprehensions revisited. Res. J. Pharm. Biol. Chem. Sci., 5: 558-563. Fasinu P.S. et al. 2016. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy, 36(7): 781-96 Jensen S. M. R., Ruscetti F. W., Rein A., Bertolette D. C., Saucedo C. J., O’Keefe B. R. and Jones K. S. 2014. Differential Inhibitory Effects of Cyanovirin-N, Griffithsin, and Scytovirin on Entry Mediated by Envelopes of Gammaretroviruses and Deltaretroviruses. J. Virol., 88: 2327-2332. Jing J. L. J., Yi T. P., Bose R. J. C., McCarthy J. R., Tharmalingam N. and Madheswaran T. 2020. Hand sanitisers: A review on formulation aspects, adverse effects, and regulations. Int. J. Environ. Res. Public Health, 17: 3326 - 3343. Kinane DF, Stathopoulou PG and Papapanou PN. 2017. Periodontal diseases. Nature Reviews- Disease Primers, 3: 17038. doi:10.1038 / nrdp.2017.38 Martinenghi L. D., Jonsson R., Lund T. and Jenssen H. 2020. Isolation, Purification, and Antimicrobial Characterization of Cannabidiolic Acid and Cannabidiol from Cannabis sativa L. Biomolecules, 10: 1-15. Mitchell C. A., Ramessar K. and O’Keefe B, R. 2017. Antiviral lectins: Selective inhibitors of viral entry. Antivir. Res., 142: 37 - 54. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65 (1-2): 55-63 Murthy, S. and H. Shivakumar. 2010. Topical and transdermal drug delivery. Handbook of Non-Invasive Drug Delivery Systems, 1-36. Nakano Y, Tajima M, Sugiyama E, Sato VH and Sato Hitoshi. 2019. Development of a novel nanoemulsion formulation to improve intestinal absorption of Cannabidiol. Medical Cannabis and Cannabinoids, 2: 35-42 Nguyen M.T., Hanzelmann D., Haertner T., Peschel A. and Goetz F. 2015. Skin-specific unsaturated fatty acids boost the staphylococcus aureus innate immune response. Infect Immun., 84: 205-215. Pawan P., Mayur P. and Ashwin S. 2011. Role of natural polymers in sustained release drug delivery system; International Research Journal of Pharmacy, 2: 6-11 Ramer R. and Hinz B. 2017. Chapter twelve- Cannabinoids as anticancer drugs. Advances in Pharmacology, 80: 397-436; Ravi et al. 2017: Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model. Journal of Pharmacy and Pharmacology, 69: 823-833 Sattar, S.A. Microbicides and the environmental control of nosocomial viral infections. J. Hos. Infect. 56 (2004) 64-69. Seo G., Lee G., Kim M.J., Baek S.-H., Choi M., Ku K. B., Lee C.-S., Jun S., Park D., Kim H. G., Kim S.-J., Lee J. -O., Kim B. K, Park E. C. and Kim S. I. 2020. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano, 14: 5135-5142 Wassmann C.S., Hojrup P. and Klitgaard J.K. 2020. Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria. Sci. Rep., 10: 4112. Wang et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30: 269-271. Shrivastava A, Kuzontkoski PM, Groopman JE and Prasad A. 2011. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. American Association for Cancer Research, 10 (7): 1161-72 Zhang X, Qin Y, Pan Z, Li M, et al (b). 2019. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC-7901 cell. Biomolecules 9, 302 Zhang Y, Ge Y, Shi W, Hu C, et al (a). 2019. CDS-1548 induces apoptosis in HeLa cells by activating caspase 3. Oncology Letters, 18: 1881-1887

Claims

1. 1. A process for producing an alcohol-free antimicrobial moisturizing hand sanitizer, comprising: (i) A. I. Co-dissolving at least one hydrophobic active compound selected from cannabidiol (CBD) and palmitic acid (PA) and at least one copolymer in a polar aprotic solvent; A. II. Adding a surfactant to form an organic phase; A. III. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer to form a nanoemulsion; and A. IV. Stabilizing the nanoemulsion by stirring or B. V. Dissolving at least one copolymer in a polar aprotic solvent; B. VI. Adding a surfactant to form an organic phase; B. VII. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from cyanovirin-N (CV-N) to form a nanoemulsion; and B. VIII. Stabilizing the nanoemulsion by stirring or C. V. Co-dissolving at least one hydrophobic active compound selected from CBD, PA or both and at least one copolymer in a polar aprotic solvent; C. VI. Adding a surfactant to form an organic phase; C. VII. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from CV-N to form a nanoemulsion; and C. VIII. Stabilizing the nanoemulsion by stirring producing a polymer-based nanoemulsion comprising: (ii) D.I. Mixing the xanthan gum into the glycerol with stirring until it is completely dispersed in the glycerol; and D. II. Adding water and preservatives including citric acid and stirring to form an aqueous gel-like moisturizing composition. preparing the aqueous gel-like moisturizing composition, (iii) mixing the stabilized nanoemulsion of step (i) with the aqueous gel-like moisturizing composition of step (ii) to form the alcohol-free antimicrobial moisturizing hand sanitizer; A process including.

2. 1. A process for producing an alcohol-free antimicrobial moisturizing hand sanitizer, comprising: (i) A. I. Co-dissolving at least one hydrophobic active compound selected from cannabidiol (CBD) and palmitic acid (PA) and at least one copolymer in a polar aprotic solvent; A. II. Adding a surfactant to form an organic phase; A. III. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer to form a nanoemulsion; and A. IV. Stabilizing the nanoemulsion by stirring or B. V. Dissolving at least one copolymer in a polar aprotic solvent; B. VI. Adding a surfactant to form an organic phase; B. VII. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from cyanovirin-N (CV-N) to form a nanoemulsion; and B. VIII. Stabilizing the nanoemulsion by stirring or C. V. Co-dissolving at least one hydrophobic active compound selected from CBD and PA and at least one copolymer in a polar aprotic solvent; C. VI. Adding a surfactant to form an organic phase; C. VII. Dispersing the organic phase in an aqueous mixture containing at least one hydrophilic polymer and at least one hydrophilic active compound selected from CV-N to form a nanoemulsion; and C. VIII. Stabilizing the nanoemulsion by stirring producing a polymer-based nanoemulsion comprising: (ii) D.I. Mixing the xanthan gum into the glycerol with stirring until it is completely dispersed in the glycerol; and D. II. Adding water and a preservative selected from citric acid and stirring to form an aqueous gel-like moisturizing composition. preparing the aqueous gel-like moisturizing composition; (iii) mixing the stabilized nanoemulsion of step (i) with the aqueous gel-like moisturizing composition of step (ii) to form the alcohol-free antimicrobial moisturizing hand sanitizer; A process consisting of:

3. The process of claim 1 or 2, wherein the at least one copolymer is selected from the group consisting of poly(lactic-co-glycolic acid), polylactic acid, polyglycolic acid, and poly-ε-caprolactone.

4. 3. The process of claim 1 or 2, wherein the at least one copolymer is poly(lactic-co-glycolic acid).

5. 5. The process of any one of claims 1 to 4, wherein the polar aprotic solvent is selected from any one or more of ethanol, acetone, and a blend of ethanol and acetone.

6. 6. The process of claim 5, wherein the polar aprotic solvent is a co-solution of acetone / ethanol (3:1).

7. The process according to any one of claims 1 to 6, wherein the surfactant is selected from any surfactant having a hydrophilic-lipophilic balance (HLB) value greater than 10.

8. 8. The process of claim 7, wherein the surfactant is polysorbate 80.

9. 9. The process according to any one of claims 1 to 8, wherein the at least one hydrophilic polymer is selected from the group consisting of any one or more of polyvinyl alcohol (PVA) and polyethylene glycol (PEG).

10. 10. The process of claim 9, wherein the at least one hydrophilic polymer is hydrolyzed PVA.

11. 11. The process of any one of claims 1 to 10, wherein the phosphate buffer has a pH of about 7.2 to about 7.6 at 0°C, including any possible subrange or pH within this range.

12. An alcohol-free antimicrobial moisturizing hand sanitizer produced according to the process of any one of claims 1 to 11.

13. (a) CV-N, CBD or PA; (b) both CV-N and CBD, or both CBD and PA, or both CV-N and PA; and (c) All three of CV-N, CBD, and PA.

13. The hand sanitizer of claim 12, comprising an active compound selected from any one of the following:

14. 14. The hand sanitizer of claim 12 or 13 for use with an antimicrobial agent, including any one or more of an antibacterial agent, an antiviral agent, or an antifungal agent.

15. The polymer-based nanoemulsion comprises: i. an inner nanoemulsion matrix composed of a polar aprotic solvent, at least one copolymer and a surfactant; ii. an outer shell comprising one or more hydrophilic polymers and a buffer; iii. one or more of the active compounds; 15. The hand sanitizer of any one of claims 12-14, wherein if the active compound is hydrophobic, the active compound is contained within the inner nanoemulsion matrix, and if the active compound is hydrophilic, the active compound is contained within the outer shell.

16. The polymer-based nanoemulsion comprises: A. a) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, a surfactant, and one or more active compounds selected from CBD and PA; A. b) an outer shell consisting of one or more hydrophilic polymers and a buffer; or B. c) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, and a surfactant; B. a) an outer shell consisting of one or more hydrophilic polymers, a buffer, and an active compound selected from CV-N; or C. a) an inner nanoemulsion matrix consisting of a polar aprotic solvent, at least one copolymer, a surfactant, and any one or more active compounds selected from CBD and PA; C. b) an outer shell consisting of one or more hydrophilic polymers, a buffer, and an active compound selected from CV-N; The hand sanitizer according to any one of claims 12 to 14, comprising:

17. 17. The hand sanitizer of any one of claims 12 to 16, wherein the aqueous solution of hydrophilic polymer is selected from any one or more of polyvinyl alcohol (PVA) and polyethylene glycol (PEG).

18. 18. The hand sanitizer of claim 17, wherein the hydrophilic polymer is hydrolyzed PVA.

19. 19. The hand sanitizer of any one of claims 12 to 18, wherein the at least one copolymer is selected from the group consisting of poly(lactic-co-glycolic acid), polylactic acid, polyglycolic acid, and poly-ε-caprolactone.

20. 20. The hand sanitizer of claim 19, wherein the copolymer is poly(lactic-co-glycolic acid).

21. 21. The hand sanitizer of any one of claims 12 to 20, wherein the polar aprotic solvent is selected from the group consisting of ethanol, acetone, and blends thereof.

22. 22. The hand sanitizer of claim 21, wherein the polar aprotic solvent is a co-solution of acetone / ethanol (3:1).

23. 23. The hand sanitizer of any one of claims 12 to 22, wherein the surfactant has a hydrophilic-lipophilic balance (HLB) value greater than 10 and includes polysorbate 80.

24. The hand sanitizer of any one of claims 12 to 23, wherein the buffer is phosphate buffered saline (PBS).

25. A method for sanitizing hands and optionally surfaces with an alcohol-free, antimicrobial, moisturizing hand sanitizer according to any one of claims 12 to 24.

26. A method for inhibiting microorganisms, including bacteria, viruses and fungi, by use of an alcohol-free antimicrobial moisturizing hand sanitizer according to any one of claims 12 to 24.

27. 27. The method of claim 25 or 26, wherein the microorganism is a virus, including any one or more of HIV-1 or a coronavirus, including SARS-CoV-2 or MERS-CoV.

28. Use of the alcohol-free antimicrobial moisturizing hand sanitizer of any one of claims 12 to 24 in a method for hand hygiene and / or for inhibiting microorganisms, including bacteria, viruses and fungi.

29. 29. The use of claim 28, wherein the microorganism is a virus, including any one or more of HIV-1 or a coronavirus, including SARS-CoV-2 or MERS-CoV.

Citation Information

Patent Citations

  • Cannabidiol nano-micelle preparation and preparation method thereof

    CN113197852A

  • Glycosylation-Resistant Cyanovirins and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Making and Using Non-Glycosylated Cyanovirins

    JP2004535784A

  • Moisturizing cosmetic composition containing a combination of homarin and erythritol

    JP2011512397A

  • Germicidal detergent

    JP2015091992A

  • Process for producing a nano-CBD microemulsion system

    US20190365647A1